Holen Sie sich die Stockscreener-App
0.00
100.00%
-7.15
Handel nachbörslich:
7.14
7.14
+
G 1 Therapeutics Inc Aktie (GTHX) Neueste Nachrichten
Layoff Tracker: Bavarian, BenevolentAI, Chroma Medicine and Nvelop Therapeutics Cut Staff - BioSpace
Indapta Therapeutics Announces Clinical Study Collaboration With Sanofi on Multiple Myeloma Program - Business Wire
Earnings Flash (GTHX) G1 THERAPEUTICS Posts Q3 Revenue $12.3M, vs. Street Est of $14.2M - Marketscreener.com
G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer - Marketscreener.com
G1 Therapeutics, Inc. Announces Management Changes - Marketscreener.com
Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q1 Revenue $12.9M, vs. Street Est of $11.4M - Marketscreener.com
Insider Sell: G1 Therapeutics - Marketscreener.com
G1 Therapeutics, Inc. Announces Executive Changes - Marketscreener.com
ScaleReady Announces a G-Rex® Grant has been awarded to Luminary Therapeutics - Yahoo Finance
Needham Adjusts Price Target on G1 Therapeutics to $32 From $42, Reiterates Buy Rating - Marketscreener.com
HC Wainwright Adjusts G1 Therapeutics Price Target to $57 From $67, Maintains Buy Rating - Marketscreener.com
G1 Therapeutics Says Study Confirms Myelosuppression Risk In Patients Getting Chemotherapy for Lung Cancer - Marketscreener.com
G1 Therapeutics Says Phase 2 Trial Shows Objective Response Rate of 40% in Patients With Bladder Cancer - Marketscreener.com
Needham Adjusts Price Target on G1 Therapeutics to $31 From $32, Maintains Buy Rating - Marketscreener.com
G1 Therapeutics : to Provide Third Quarter 2020 Corporate and Financial Update on November 4, 2020 - Marketscreener.com
G1 Therapeutics : to Provide Second Quarter 2020 Corporate and Financial Update on August 5, 2020 - Marketscreener.com
G1 Therapeutics to End Colorectal Cancer Trial of Drug Therapy; Shares Plunge - Marketscreener.com
G1 Therapeutics Says Trilaciclib Shows Potential for Improved Clinical Outcome in Phase 2 Breast Cancer Trial - Marketscreener.com
G-Protein Coupled Receptors Market Growth Analysis, Trends, Share, Market Size And Forecast To 2033 - WhaTech
46,234 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Acquired by Federated Hermes Inc. - Defense World
Global study predicts sharp rise in cancer rates among men by 2050 - Benefits and Pensions Monitor
Edgewise Therapeutics (EWTX) Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy - StreetInsider.com
Edgewise Therapeutics, Inc Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy - Marketscreener.com
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) - Business Wire
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer - GlobeNewswire
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer - Benzinga
why G1 Therapeutics Inc [GTHX] is a Good Choice for Investors After New Price Target of $7.15 - The DBT News
G1 Therapeutics Inc [GTHX] Insider Perry Andrew sells 1,337 Shares - Knox Daily
G1 Therapeutics Inc: Navigating a Turbulent Year, Up -0.70% from 52-Week Low - The InvestChronicle
Acadian Asset Management LLC Increases Stake in G1 Therapeutics, Inc. (NASDAQ:GTHX) - MarketBeat
Insider Selling: Perry Andrew, G1 Therapeutics Inc [GTHX] Chief Commercial Officer divested 1,337 shares - Knox Daily
Recent Insider Activity Could Benefit G1 Therapeutics Inc (GTHX) - Knox Daily
Exploring High Growth Tech Stocks in the United States for September 2024 - Simply Wall St
Pharmacosmos moves forward with G1 Therapeutics buyout - Investing.com India
GTHXG1 Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period - GlobeNewswire
Keeping an Eye on G1 Therapeutics Inc (GTHX) After Insider Trading Activity - Knox Daily
Panagora Asset Management Inc. Buys New Shares in G1 Therapeutics, Inc. (NASDAQ:GTHX) - MarketBeat
A company insider recently sold 1,337 shares of G1 Therapeutics Inc [GTHX]. Should You Sale? - Knox Daily
The Significance of Moving Averages in G1 Therapeutics Inc Inc. (GTHX) Price Performance - The InvestChronicle
G1 Therapeutics Inc (GTHX) gets rating Upgrade from JP Morgan - Knox Daily
Stock Market Recap: G1 Therapeutics Inc (GTHX) Concludes at 7.12, a 0.28 Surge/Decline - The Dwinnex
It is Poised to be a Bull Market for G1 Therapeutics Inc (GTHX) - SETE News
G1 Therapeutics Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - The InvestChronicle
It would be worthwhile to take a closer look at G1 Therapeutics Inc (GTHX) - US Post News
Monopar Receives Clearance to Proceed with Phase 1 - GlobeNewswire
Stock Market Recap: G1 Therapeutics Inc (GTHX) Concludes at 7.09, a -0.28 Surge/Decline - The Dwinnex
Finansavisen - Finansavisen
The Potential Rise in the Price of G1 Therapeutics Inc (GTHX) following insiders activity - Knox Daily
A look into G1 Therapeutics Inc (GTHX)’s deeper side - SETE News
FDA Allows Resumption Of BioNTech/MediLink Therapeutics Partnered Phase 1 Study For Cancer Drug With Lower Dose - Yahoo Finance
G1 Therapeutics, Inc. (NASDAQ:GTHX) Position Raised by Vanguard Group Inc. - MarketBeat
Vanguard Group Inc. Raises Stock Holdings in G1 Therapeutics, Inc. (NASDAQ:GTHX) - Defense World
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Pharmacosmos ventures into oncology and merges with G1 Therapeutics - MSN
TG Therapeutics Receives Clearance from FDA for Phase 1 Trial in Multiple Sclerosis for Allogeneic CAR-T Azer-Cel - CGTLive™
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates - MSN
G1 Therapeutics surges on merger deal with Pharmacosmos - MSN
Lowenstein Represents Crown Laboratories in Merger Agreement with Revance Therapeutics, Inc. - Lowenstein Sandler LLP
Q3 2024 EPS Estimates for G1 Therapeutics, Inc. (NASDAQ:GTHX) Raised by Analyst - Defense World
Q3 2024 EPS Estimates for G1 Therapeutics, Inc. Lifted by Analyst (NASDAQ:GTHX) - MarketBeat
Pharmacosmos Group’s Acquisition of G1 Therapeutics - Global Legal Chronicle
G1 Therapeutics, Inc. (NASDAQ:GTHX) Expected to Earn Q3 2025 Earnings of ($0.04) Per Share - Defense World
G1 Therapeutics (NASDAQ:GTHX) Issues Quarterly Earnings Results, Beats Estimates By $0.07 EPS - Defense World
G1 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of G1 Therapeutics, Inc.GTHX - Business Wire
Wedbush Equities Analysts Cut Earnings Estimates for G1 Therapeutics, Inc. (NASDAQ:GTHX) - MarketBeat
G1 Therapeutics (NASDAQ:GTHX) Rating Reiterated by Needham & Company LLC - Defense World
HC Wainwright Lowers G1 Therapeutics (NASDAQ:GTHX) to Hold - Defense World
FY2027 Earnings Estimate for G1 Therapeutics, Inc. (NASDAQ:GTHX) Issued By Wedbush - Defense World
G1 Therapeutics (GTHX) Shares Surge Following Acquisition Announcement - The Fosters Leader
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):